Two biotech companies, both developing promising therapeutics with strong scientific teams. In a board meeting, someone asks: "where do

We had a call this month with an SVP who's taken 11 compounds into clinic, across 6 biotechs.

In most biopharma organizations, the data story is the same. You have information scattered across every imaginable system: LIMS, ELNs,

Why is it so hard to get answers to pretty straightforward questions, when it comes to biotech data? And what

A significant limitation of AI-driven biotech has been the training data. With so many models drawing on the same pool

Cutting out two hours often means saving two weeks. Below, we cover why productivity gains can be such a powerful

When I was seven years old, my mom was diagnosed with leukemia. We were a freshly immigrated family, still figuring

As a biotech company, every resource - minute, dollar, and FTE focus - counts in your race to reach market.

What does it take to effectively commercialize a drug? How can biotech leaders successfully navigate this long, winding, and expensive

The most misguided assumption in biotech investing right now is that tough markets hurt everyone equally. We've been